About Transcription factor Dp-1
Transcription factor Dp-1 (TFDP1) is a protein
from Homo sapiens identified by UniProt accession
Q14186, 410 residues long.
MolForge cross-references it against 0 known binders and
106 disease associations.
Target properties
| Protein name | Transcription factor Dp-1 |
|---|
| UniProt accession | Q14186 |
|---|
| Gene | TFDP1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 410 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (106)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.45
- lung adenocarcinoma · score 0.31
- glioblastoma multiforme · score 0.30
- endometrial cancer · score 0.29
- head and neck squamous cell carcinoma · score 0.29
- ovarian cancer · score 0.29
- mean corpuscular volume · score 0.29
- breast adenocarcinoma · score 0.29
- squamous cell lung carcinoma · score 0.28
- gastric adenocarcinoma · score 0.28
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q14186-F1 | alphafold | PREDICTED | 69.77 | — |
Amino-acid sequence (410 residues)
MAKDAGLIEA NGELKVFIDQ NLSPGKGVVS LVAVHPSTVN PLGKQLLPKT FGQSNVNIAQ QVVIGTPQRP AASNTLVVGS PHTPSTHFAS QNQPSDSSPW SAGKRNRKGE KNGKGLRHFS MKVCEKVQRK GTTSYNEVAD ELVAEFSAAD NHILPNESAY DQKNIRRRVY DALNVLMAMN IISKEKKEIK WIGLPTNSAQ ECQNLEVERQ RRLERIKQKQ SQLQELILQQ IAFKNLVQRN RHAEQQASRP PPPNSVIHLP FIIVNTSKKT VIDCSISNDK FEYLFNFDNT FEIHDDIEVL KRMGMACGLE SGSCSAEDLK MARSLVPKAL EPYVTEMAQG TVGGVFITTA GSTSNGTRFS ASDLTNGADG MLATSSNGSQ YSGSRVETPV SYVGEDDEED DDFNENDEDD
Explore Transcription factor Dp-1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets